94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Microbiol.
Sec. Infectious Agents and Disease
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1558482
Advancements in the application and research of baculovirus vector vaccines for respiratory diseases in human
Provisionally accepted
Jinghua Yuan 1
Jingyu Chen 1 Qingzhi Zhao 1 Jialu Xu 1 Xianwei Li 1
Yijie Zhang 1 Hairun Li 1 Xintong Chen 1 Ling Zhao 1 Xiaofen Zhang 1
Hongyu Li 2*
Keda Chen 1*- 1 Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Jiangsu Province, China
- 2 Zhejiang Shuren University, Hangzhou, China
The rapid spread of respiratory diseases, such as influenza, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Respiratory Syncytial Virus (RSV), poses significant challenges to global public health systems. Vaccination remains the most effective strategy to mitigate these threats. Baculovirus Expression Vector Systems (BEVS) have emerged as a promising platform for vaccine development, addressing key limitations of traditional methods, including complex production processes, lengthy timelines, and high costs. BEVS offers distinct advantages, such as enhanced efficacy, safety, cost-effectiveness, and scalability for large-scale manufacturing. This review highlights the application of BEVS in combating respiratory diseases by analyzing preclinical studies, clinical trials, and approved vaccines targeting these pathogens. It also examines recent advancements in BEVS technology, emphasizing its capacity to accelerate vaccine development and respond to emerging respiratory threats. By focusing on the synergy between BEVS and respiratory disease prevention, this review provides valuable insights to guide global vaccine innovation.
Keywords: Baculovirus1, vaccine2, respiratory disease3, Preclinical study4, clinical application5
Received: 10 Jan 2025; Accepted: 25 Feb 2025.
Copyright: © 2025 Yuan, Chen, Zhao, Xu, Li, Zhang, Li, Chen, Zhao, Zhang, Li and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Hongyu Li, Zhejiang Shuren University, Hangzhou, China
Keda Chen, Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Jiangsu Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.